drugset / Trial / NCT00103662

Mobilization of Stem Cells With AMD3100 (Plerixafor) in Multiple Myeloma Patients

NCT00103662

Phase 3 Completed 302 enrolled Genzyme, a Sanofi Company
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine whether the combination of AMD3100 (plerixafor) and granulocyte colony-stimulating factor (G-CSF, generic name of filgrastim) is better than G-CSF alone to mobilize and collect the optimal number of stem cells in multiple myeloma patients for autologous transplantation.

Timeline

Start
2005-01
Primary completion
2006-10
Completion
2008-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Plerixafor Small molecule 240 ug/kg Subcutaneous
Background filgrastim Protein / enzyme biologic 10 ug/kg Subcutaneous

Indications